Dynavax Technologies (NASDAQ:DVAX – Get Free Report) and Appili Therapeutics (OTCMKTS:APLIF – Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, profitability, earnings, dividends, analyst recommendations, valuation and institutional ownership.
Institutional and Insider Ownership
97.0% of Dynavax Technologies shares are owned by institutional investors. 3.0% of Dynavax Technologies shares are owned by company insiders. Comparatively, 11.8% of Appili Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Dynavax Technologies and Appili Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Dynavax Technologies | -16.67% | 5.10% | 3.00% |
| Appili Therapeutics | N/A | N/A | -107.24% |
Volatility and Risk
Analyst Recommendations
This is a summary of recent recommendations for Dynavax Technologies and Appili Therapeutics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Dynavax Technologies | 1 | 0 | 3 | 0 | 2.50 |
| Appili Therapeutics | 0 | 0 | 0 | 0 | 0.00 |
Dynavax Technologies currently has a consensus price target of $24.33, indicating a potential upside of 145.30%. Given Dynavax Technologies’ stronger consensus rating and higher possible upside, research analysts plainly believe Dynavax Technologies is more favorable than Appili Therapeutics.
Earnings & Valuation
This table compares Dynavax Technologies and Appili Therapeutics”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Dynavax Technologies | $277.25 million | 4.20 | $27.31 million | ($0.46) | -21.57 |
| Appili Therapeutics | $70,000.00 | 20.79 | -$1.89 million | ($0.01) | -1.20 |
Dynavax Technologies has higher revenue and earnings than Appili Therapeutics. Dynavax Technologies is trading at a lower price-to-earnings ratio than Appili Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Dynavax Technologies beats Appili Therapeutics on 9 of the 14 factors compared between the two stocks.
About Dynavax Technologies
Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.
About Appili Therapeutics
Appili Therapeutics Inc., a biopharmaceutical company, focuses on the acquisition and development of novel medicines for unmet needs in infectious disease in Canada. Its anti-infective portfolio includes ATI-1501, a taste-masked liquid oral suspension formulation of the antibiotic metronidazole to treat anaerobic bacterial, protozoal, and parasitic infections; ATI-1801, a novel topical formulation of paromomycin in Phase III clinical trials for the treatment of cutaneous leishmaniasis and disfiguring skin infections; and ATI-1701, which is a live-attenuated vaccine in preclinical trials for Francisella tularensis. The company was incorporated in 2015 and is headquartered in Halifax, Canada.
Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
